ReNeuron

ReNeuron Group Plc is engaged in the research, development, and commercial development of stem cell technologies for therapeutic and non-therapeutic applications. It has developed a range of stem cell therapies for neurodegenerative diseases and other conditions, including Parkinson's disease, Type 1 diabetes, and retinal disorders. The company’s therapeutic pipeline includes ReN001, a pre-clinical stage therapy targeting disabled stroke patients.